K
Kiyotaka Yoh
Publications - 220
Citations - 5121
Kiyotaka Yoh is an academic researcher. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 29, co-authored 196 publications receiving 3872 citations.
Papers
More filters
Journal ArticleDOI
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
James Chih-Hsin Yang,Myung-Ju Ahn,Dong Wan Kim,Suresh S. Ramalingam,Lecia V. Sequist,Wu Chou Su,Sang We Kim,Joo Hang Kim,David Planchard,Enriqueta Felip,Fiona H Blackhall,Daniel Haggstrom,Kiyotaka Yoh,Silvia Novello,Kathryn A. Gold,Tomonori Hirashima,Chia-Chi Lin,Helen Mann,Mireille Cantarini,Serban Ghiorghiu,Pasi A. Jänne +20 more
TL;DR: In patients with EGFRm T790M advanced NSCLC who progress after EGFR-TKI treatment, osimertinib provides a high ORR, encouraging PFS, and durable response, and this article reports the results from the phase II extension component.
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean-Charles Soria,Yi-Long Wu,Kazuhiko Nakagawa,Sang We Kim,Jin Ji Yang,Myung-Ju Ahn,Jie Wang,James Chih-Hsin Yang,You Lu,Shinji Atagi,Santiago Ponce,Dae Ho Lee,Yunpeng Liu,Kiyotaka Yoh,Jianying Zhou,Xiaojin Shi,Alan Webster,Haiyi Jiang,Tony Mok +18 more
TL;DR: The IMPRESS trial as discussed by the authors evaluated the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefinib.
Journal ArticleDOI
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh,Takashi Seto,Miyako Satouchi,Makoto Nishio,Noboru Yamamoto,Haruyasu Murakami,Naoyuki Nogami,Shingo Matsumoto,Takashi Kohno,Koji Tsuta,Katsuya Tsuchihara,Genichiro Ishii,Shogo Nomura,Akihiro Sato,Atsushi Ohtsu,Yuichiro Ohe,Koichi Goto +16 more
TL;DR: Vandetanib showed clinical antitumour activity and a manageable safety profile in patients with advanced RET-rearranged NSCLC, defining RET rearrangement as a new molecular subgroup ofNSCLC suitable for targeted therapy.
Journal ArticleDOI
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Kiyotaka Yoh,Genichiro Ishii,Tomoyuki Yokose,Yuji Minegishi,Kohji Tsuta,Koichi Goto,Yutaka Nishiwaki,Tetsuro Kodama,Moritaka Suga,Atsushi Ochiai +9 more
TL;DR: Positive immunostaining for BCRP appears to be a predictor of survival in patients with advanced NSCLC, indicating that B CRP may serve as a molecular target for reducing drug resistance to chemotherapy in advancedNSCLC patients.